c-Kit-IN-3
CAS No. 2363169-01-9
c-Kit-IN-3( —— )
Catalog No. M26080 CAS No. 2363169-01-9
c-Kit-IN-3 is a selective inhibitor of c-KIT kinase with IC50s of 4 nM and 8 nM for c-Kit (wt) and c-Kit (T670I).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 248 | Get Quote |
|
10MG | 401 | Get Quote |
|
25MG | 662 | Get Quote |
|
50MG | 888 | Get Quote |
|
100MG | 1242 | Get Quote |
|
500MG | 2502 | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product Namec-Kit-IN-3
-
NoteResearch use only, not for human use.
-
Brief Descriptionc-Kit-IN-3 is a selective inhibitor of c-KIT kinase with IC50s of 4 nM and 8 nM for c-Kit (wt) and c-Kit (T670I).
-
Descriptionc-Kit-IN-3 is a selective inhibitor of c-KIT kinase with IC50s of 4 nM and 8 nM for c-Kit (wt) and c-Kit (T670I).(In Vitro):In primary GIST patient cells, c-Kit-IN-3 (0.1-10 μM) exhibits dose-dependent antiproliferative effects. In GIST-T1, GIST-T1-T670I, and GIST-5R cells, c-Kit-IN-3 (0.01-1 μM) induces dose-dependent cell apoptotic death and arrests the cell cycle into the G0/G1 phase.(In Vivo):c-Kit-IN-3 (1 mg/kg i.v. for mice, rats, dog; 10 mg/kg p.o. for mice, rats; 5 mg/kg p.o. for dog) has T1/2 of 4.5 h, 6.4 h, 19.4 h for mice, rats and dogs, respectively. c-Kit-IN-3 possesses acceptable bioavailability of 43%, 50% and 81% for mice, rats, and dogs. In female BALB/C-nu mice, c-Kit-IN-3 (20-100 mg/kg; gavage) treatment dose-dependently inhibits the tumor progression.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
Targetc-Kit
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2363169-01-9
-
Formula Weight516.9
-
Molecular FormulaC26H20ClF3N2O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOc1cc2nccc(Oc3ccc(NC(=O)Cc4ccc(Cl)c(c4)C(F)(F)F)cc3)c2cc1OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
OSI-930
A potent, orally active, dual inhibitor of c-Kit and VEGFR-2 (KDR) with IC50 of 15 nM and 9 nM, respectively.
-
AZD2932
AZD2932 is a new series of quinazoline ether inhibitor which potently inhibits VEGFR-2 and PDGFR with IC50s of 4 nM/8 nM/ 7 nM for PDGFRβ/VEGFR-2/Flt-3.
-
Apatinib
Apatinib is an orally bioavailable, selective VEGFR2 inhibitor with IC50 of 1 nM.